GCVI Summit 2018
Skip Content

6 October 2017

Corporates find Harmony in $270m round

Novo and Nan Fung Life Sciences are among the investors as Harmony Biosciences, which focuses on central nervous system disorders.

Author: Robert Lavine, News Editor

US-based biopharmaceutical company Harmony Biosciences closed a $270m funding round yesterday that included pharmaceutical firm Novo and Nan Fung Life Sciences, a subsidiary of property developer Nan Fung.